Real-world Standing Cohorts
The Real-World Standing Cohort study is a data analytical project which provides insight into the patient pathway to understand how cancer treatments are working and where improvements can be made. Health Data Insight works in partnership with the National Cancer Registration and Analysis Service and several pharmaceutical companies to provide analysis into anti-cancer treatments to improve patient care.
The anti-cancer treatment landscape has advanced rapidly in recent years, particularly within the field of immune-oncology. Although the development of novel drugs is subject to multiple phases of stringent clinical trials, these trials are subject to notable shortcomings, including their small size, short durations and selection of patients that are often healthier than the real-world target population.
In this context, there is growing interest among pharmaceutical companies in better understanding the conventional treatment pathway, healthcare resource utilisation and survival of patients within target populations for novel immune-oncology agents, as well as the comparative performance of novel agents once approved for use in the real world under the Cancer Drugs Fund.
Routinely-collected data can provide valuable insights in this respect, providing timely and detailed information on population-level patient groups, following their treatment and contact with NHS-funded secondary care services over many years.
HDI works with several pharmaceutical companies with the aim of providing such insights. These data can then be used by the pharmaceutical companies to help inform the health technology appraisal processes of NICE, with a view to determining whether a novel therapy should be approved for routine commissioning across NHS England and for which indication(s).
In collaboration with:
Chouaid, C., Bosquet, L., Girard, N. et al. An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations. Adv Ther 40, 1187–1203 (2023). https://doi.org/10.1007/s12325-022-02408-7 Published 18 January 2023 https://rdcu.be/dfEHr